Difference between revisions of "Tivantinib (ARQ-197)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
Warner-admin (talk | contribs) m (Warner-admin moved page Tivantinib (ARQ 197) to Tivantinib (ARQ-197) without leaving a redirect) |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 8: | Line 8: | ||
==Patient drug information== | ==Patient drug information== | ||
No information available. | No information available. | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' ARQ-197 | ||
==References== | ==References== | ||
| Line 15: | Line 18: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | + | ||
[[Category:MET inhibitors]] | [[Category:MET inhibitors]] | ||
| − | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Latest revision as of 00:46, 29 July 2023
General information
Class/mechanism: C-Met inhibitor. Inappropriate or constitutive activation of the receptor tyrosine kinase c-Met and its signalling pathway is implicated in many cancers, playing a role in abnormal proliferation, survival, invasion, metastasis, and angiogenesis.[1]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Patient drug information
No information available.
Also known as
- Code name: ARQ-197